Welcome to our dedicated page for Smith & Nephew SEC filings (Ticker: SNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Smith & Nephew plc files as a foreign private issuer whose SEC reports document a global medical technology business and its NYSE-traded American depositary receipts. Form 6-K reports cover trading updates, product and strategy communications, annual meeting results, dividend approvals, voting rights and capital, share buyback programs, and ordinary-share matters underlying the ADR program.
The filing record also includes disclosures on board elections, remuneration votes, treasury shares, share-plan awards under the RISE Share Plan, PDMR transactions, forward-looking statements, and business-unit performance across Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. These filings link the company’s UK corporate governance and capital structure to its U.S. reporting obligations under Form 20-F foreign-issuer status.
Smith & Nephew plc reported routine share purchases by its Chief Executive Officer and senior managers through an employee plan linked to dividend reinvestment. The Company’s Employee Stock Purchase Plan bought American Depositary Shares (ADS) under the Dividend Re-Investment Plan following the 2025 final dividend paid on 27 May 2026.
On 3 June 2026, ADS in Smith & Nephew plc were acquired on the New York Stock Exchange at a price of $29.8328 per ADS. Participants included CEO Deepak Nath, the Chief Quality & Regulatory Affairs Officer, the President of Global Operations, and the President of Sports Medicine.
Cevian Capital II GP Limited has updated its ownership disclosure for Smith & Nephew plc, reporting beneficial ownership of 101,046,788 ordinary shares. This represents 11.88% of the company’s ordinary shares, based on 850,209,708 shares outstanding as of May 31, 2026.
The shares were acquired for approximately USD $1,415,913,326, funded from the Cevian funds’ general working capital and purchased in British pounds using a conversion rate of USD $1.34725 per GBP 1.00. Cevian reports sole voting and sole dispositive power over all of these shares.
Smith & Nephew plc reported routine share acquisitions by senior management under its Dividend Re-Investment Plan. Following the 2025 final dividend paid on 27 May 2026, the plan automatically purchased ordinary shares of USD 0.20 each on the London Stock Exchange for participating insiders.
Chief Executive Officer Deepak Nath acquired 6,259.14583 ordinary shares at a price of 11.38002 per share, while Chief Financial Officer John Rogers acquired 61.89914 shares at the same price. Other participants included President, Global Operations Paul Connolly, Chief Compliance Officer Alison Parkes, and President, Sports Medicine Scott Schaffner, each completing a single transaction through the plan.
Smith & Nephew plc reports that its new debt securities have been admitted to trading on the Main Market of the London Stock Exchange. The company has listed EUR 500,000,000 of 4.250 per cent. notes due 3 June 2038, issued under its U.S.$5,000,000,000 Euro Medium Term Note Programme.
The notes are supported by a base prospectus dated 17 March 2026 and a supplemental prospectus dated 15 May 2026, together forming the Prospectus. Investors are directed to the Prospectus and Final Terms, which are available online, and are reminded that the information is intended only for specified addressees as set out in those documents.
Smith & Nephew plc reports its latest share capital and voting rights position as at 31 May 2026. The company has total issued share capital of 877,733,750 ordinary shares of US20¢ each, of which 27,524,042 are held in treasury.
Because treasury shares do not carry voting rights, the company’s issued share capital with voting rights consists of 850,209,708 ordinary shares, each with one vote. Shareholders are asked to use this voting share figure as the denominator when assessing whether they must notify holdings or changes under the FCA’s Disclosure Guidance and Transparency Rules.
Smith & Nephew plc reports that an additional 8,905 Ordinary Shares of USD 0.20 each have been issued and admitted to trading on the Main Market of the London Stock Exchange. These shares arise from the company’s employee share schemes between 23 March 2026 and 21 May 2026 under an existing block admission dated 12 August 2022. Following this admission, there are 877,733,750 Ordinary Shares in issue, of which 26,452,529 are held in treasury.
Smith & Nephew plc reported the vesting of conditional share awards under its Global Share Plan 2020 for senior executive Rohit Kashyap. On 19 May 2026, Kashyap received 11,949 ordinary shares of US$0.20 each, listed on the London Stock Exchange.
Of these, 4,719 shares were sold to meet tax obligations at a price of £11.426512 per share, while 7,230 shares were retained. The transaction is disclosed as required for persons discharging managerial responsibilities under the UK Market Abuse Regulation.
Smith & Nephew plc reports an updated major shareholding notification from Cevian Capital II G.P. Limited under the UK TR-1 regime. Cevian now holds 11.183442% of Smith & Nephew’s voting rights, representing 95,512,095 voting rights attached to shares.
Within this total, Cevian Capital II Master Fund L.P. accounts for 10.005808% and Cevian Capital II Co-Investment - Series P L.P. accounts for 1.177635%. The aggregate stake has risen from 11.013663%, and the company notes that no new notification threshold has been crossed as a result of this increase.
Smith & Nephew plc reports that investment entities linked to Cevian Capital have crossed a major shareholding threshold. Cevian-controlled funds now hold 94,062,095 voting rights in Smith & Nephew, representing 11.013663% of voting rights attached to shares.
The previous notified position was 10.094356% of voting rights, so this filing records a higher level of ownership. The stake is held through Cevian Capital II Master Fund L.P. with 9.836028% and Cevian Capital II Co-Investment - Series P L.P. with 1.177635%, both ultimately controlled by Cevian Capital II G.P. Limited.
Smith & Nephew plc confirms the sterling amount of its previously announced final dividend for the year ended 31 December 2025. The dividend of 24.1 US cents per ordinary share will be paid on 27 May 2026. Eligible UK-address shareholders or those electing sterling will receive 17.78 pence per share, based on the company’s determined exchange rate, to holders on the register at the close of business on 27 March 2026.